News coverage about Dimension Therapeutics (NASDAQ:DMTX) has been trending positive on Friday, AlphaOne reports. AlphaOne, a unit of Accern, identifies positive and negative press coverage by reviewing more than twenty million news and blog sources in real time. AlphaOne ranks coverage of companies on a scale of -1 to 1, with scores nearest to one being the most favorable. Dimension Therapeutics earned a news sentiment score of 0.30 on AlphaOne’s scale. AlphaOne also assigned media stories about the biotechnology company an impact score of 0 out of 100, indicating that recent press coverage is extremely unlikely to have an effect on the company’s share price in the next several days.
A number of brokerages have issued reports on DMTX. Zacks Investment Research raised shares of Dimension Therapeutics from a “hold” rating to a “buy” rating and set a $1.75 target price for the company in a research note on Tuesday, April 18th. Cantor Fitzgerald set a $3.00 target price on shares of Dimension Therapeutics and gave the stock a “hold” rating in a report on Saturday, March 11th. Canaccord Genuity set a $20.00 target price on shares of Dimension Therapeutics and gave the stock a “buy” rating in a report on Saturday, March 11th. Citigroup Inc lowered shares of Dimension Therapeutics from a “buy” rating to a “neutral” rating and set a $1.50 target price on the stock. in a research report on Friday, May 12th. Finally, Jefferies Group LLC reiterated a “buy” rating and set a $7.00 target price on shares of Dimension Therapeutics in a research report on Thursday, February 2nd. Four analysts have rated the stock with a hold rating and two have given a buy rating to the company. The stock currently has an average rating of “Hold” and an average target price of $7.21.
Shares of Dimension Therapeutics (NASDAQ:DMTX) remained flat at $1.15 during mid-day trading on Friday. The company had a trading volume of 33,665 shares. The company’s market capitalization is $28.80 million. Dimension Therapeutics has a 52-week low of $1.15 and a 52-week high of $10.47. The firm has a 50-day moving average of $1.46 and a 200-day moving average of $2.97.
Dimension Therapeutics (NASDAQ:DMTX) last posted its quarterly earnings data on Wednesday, May 10th. The biotechnology company reported ($0.54) earnings per share (EPS) for the quarter, missing the Zacks’ consensus estimate of ($0.52) by $0.02. Dimension Therapeutics had a negative net margin of 464.39% and a negative return on equity of 50.07%. The business had revenue of $3.62 million for the quarter. On average, analysts anticipate that Dimension Therapeutics will post ($2.11) earnings per share for the current year.
WARNING: “Dimension Therapeutics (DMTX) Given Daily Coverage Optimism Rating of 0.30” was posted by Sports Perspectives and is owned by of Sports Perspectives. If you are viewing this story on another website, it was copied illegally and republished in violation of United States & international copyright and trademark law. The correct version of this story can be accessed at https://sportsperspectives.com/2017/05/19/dimension-therapeutics-dmtx-given-coverage-optimism-score-of-0-30-updated.html.
Dimension Therapeutics Company Profile
Dimension Therapeutics, Inc is a gene therapy company. The Company is focused on discovering and developing therapeutic products for people living with rare diseases associated with the liver and caused by genetic mutations. It has programs for hemophilia B, hemophilia A, ornithine transcarbamylase (OTC) deficiency, and glycogen storage disease type Ia (GSDIa).
Receive News & Ratings for Dimension Therapeutics Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Dimension Therapeutics Inc and related companies with MarketBeat.com's FREE daily email newsletter.